when do you see results from tirzepatide TrimRX A recap of my year

Eligible participants were adults without diabetes with a BMI of at least 30 kg/m, or at least 27 kg/m with hypertension or dyslipidaemia

Acronyms A1C - Hemoglobin A1C ADA - American Diabetes Association CVD - Cardiovascular disease DM - Diabetes mellitus FBS - Fasting blood sugar GFR - Glomerular filtration rate GI - Gastrointestinal GLP-1 - Glucagon-like peptide-1 OSA - Obstructive sleep apnea RCT - Randomized controlled trial T2DM - Type 2 diabetes mellitus Thyroid C-cell tumor = Thyroid medullary tumor DRUGS IN CLASS Dual GLP-1 and GIP agonists Tirzepatide (Mounjaro) - marketed for diabetes Tirzepatide (Zepbound) - marketed for weight loss MECHANISM OF ACTION GLP-1 and GIP GLP-1 stands for "glucagon-like peptide-1," and GIP stands for "glucose-dependent insulinotropic polypeptide." GIP is also sometimes referred to as "gastric inhibitory polypeptide." GLP-1 and GIP are hormones secreted by specialized cells in the small intestine in response to food consumption

The RxSS platform includes 228 total for weight-loss medications and 110 for GLP-1s

Back in 2022, Mette Kruse Klausen and colleagues at the University of Copenhagen published a trial in JAMA Psychiatry testing exenatide, a first-generation GLP-1 receptor agonist, against placebo in 127 patients with alcohol use disorder

Cause 2: Eating Much Less Food Many people using GLP-1 medications experience a dramatic reduction in appetite

The most immediate concern for patients with type 2 diabetes is loss of glycemic control